PSA RISING LETTERS | click for frames
")
//-->
To: [email protected]
Subject: Article on Exisulind in PSA Rising
Date sent: Thu, 8 Jun 2000 00:21:30 -0700
Thank you for the nice article about Exisulind at the link
http://www.psa-rising.com/medicalpike/exisulind2000may2.htm
which describes the results of the prostate clinical trial for Aptosyn.
I was a bit troubled by the comments of Ralph Valle who was quoted in the
sidebar and who seems to miss the point that Sulindac has two metabolites.
One is Sulindac Sulphone - Exisulind (Aptosyn) and the other is Sulindac
sulfide which he does not mention. The compound Sulindac sulfide has the
NSAID activity with its COX-1 inhibitor activity, and according to Merck,
is the active ingredient of Sulindac (Clinoril).
Unfortunately for most
patients on Sulindac, there are usually severe gastric distress side
effects from long term use of Clinoril because of the Sulindac sulfide
COX-1 inhibitor metabolite. The excitement about Aptosyn is that it can be
taken for long periods of time with no gastric side effects. If the
off-patent Sulindac which is available for low cost turns out to be too
toxic to the patient, then the patient can take Aptosyn (after FDA
approval). Cell Pathways has publicly stated that the patient cost for
Aptosyn will be around $2000 to $2500 per year.
Arthur F. Lange, Ph. D.
 E-mail
your views to [email protected] |
|
|
COVER | Upfront|
Eating Well | Voices|
Medical Pike |
Grassroots | CaPLinks |
|
prostate cancer - let's deal with it!
http://www.psa-rising.com
© 1997-2000